Sesen Bio, Inc. (SESN)
| Market Cap | 137.23M |
| Revenue (ttm) | 20.00M |
| Net Income (ttm) | 47.80M |
| Shares Out | 199.46M |
| EPS (ttm) | 0.34 |
| PE Ratio | 2.02 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,664,753 |
| Open | 0.701 |
| Previous Close | 0.718 |
| Day's Range | 0.681 - 0.737 |
| 52-Week Range | 0.365 - 1.520 |
| Beta | 0.58 |
| Analysts | Sell |
| Price Target | 0.82 (+19.2%) |
| Earnings Date | Aug 8, 2022 |
About SESN
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the tre... [Read more...]
Financial Performance
In 2021, Sesen Bio's revenue was $26.54 million, an increase of 136.24% compared to the previous year's $11.24 million. Losses were -$336,000, -98.50% less than in 2020.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for SESN stock is "Sell." The 12-month stock price forecast is 0.82, which is an increase of 19.19% from the latest price.
News
Best Momentum Stocks to Buy for August 15th
BRT, ERJ, and SESN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 15, 2022.
Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN) today reported operating results for the second quarter ended June 30, 2022. During the quarter, the Company paused clinical development of it...
What's in the Cards for Sesen Bio's (SESN) Q2 Earnings?
Sesen Bio's (SESN) Q2 performance is likely to reflect cost savings from the company's restructuring plans as the company continues to seek a potential partner for the further development of Vicineum.
Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down
Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange for an upfront payment of $40 million.
Why Shares Of Sesen Bio Are Down 28% Today
Sesen Bio Inc (NASDAQ: SESN) shares are trading lower by 28.9% at $0.66 Monday morning after the company announced that it has made the decision to voluntarily pause further development in the US of its...
Sesen Bio Pauses Clinical Development Of Its Lead Bladder Cancer Candidate In US
Based on a thorough reassessment Sesen Bio Inc (NASDAQ: SESN) has decided to voluntarily pause further development in the U.S. of its lead asset, Vicineum, for non-muscle invasive bladder cancer (NMIBC)...
Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the US
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN) today announced that it has made the strategic decision to voluntarily pause further development in the US of its lead asset, Vicineum. The de...
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Sesen Bio, Inc.
Wilmington, Delaware--(Newsfile Corp. - May 18, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Sesen Bio, Inc. (NASDAQ: SESN) on behalf of stockholde...
Sesen Bio Reports First Quarter 2022 Financial Results and Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported opera...
Sesen Bio Provides Strategic Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...
Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported opera...
Sesen Bio Further Enhances Team with Key Hires
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the ...
Why Sesen Bio Stock Got Slammed Today
The company's hopeful words about its pipeline drug fell on deaf ears.
Sesen Bio To Conduct Additional Trial For Potential Resubmission Of Vicineum In Bladder Cancer
Sesen Bio Inc (NASDAQ: SESN) has outlined its anticipated regulatory path forward for Vicineum for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) following its Clinical Type A meeting with ...
Sesen Bio Announces Anticipated Regulatory Path Forward for Vicineum™
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced its a...
Are Options Traders Betting on a Big Move in Sesen Bio (SESN) Stock?
Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. The post 7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts appeared f...
Sesen Bio Strengthens Medical Team
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the ...
Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor Role
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...
SESEN BIO, INC. (SESN) Reports Q3 Loss, Lags Revenue Estimates
SESEN BIO, INC. (SESN) delivered earnings and revenue surprises of 71.43% and -100.00%, respectively, for the quarter ended September 2021.
Sesen Bio Reports Third Quarter 2021 Financial Results and Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported opera...
SESEN BIO, INC. (SESN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
SESEN BIO, INC. (SESN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.